Skip to main content
. Author manuscript; available in PMC: 2025 Aug 15.
Published in final edited form as: Sci Transl Med. 2024 Nov 20;16(774):eadl2184. doi: 10.1126/scitranslmed.adl2184

Fig. 7. Inhibition of SUMOylation with TAK-981 improves colitis outcomes in mice.

Fig. 7.

(A) DAI, (B) body weight, (C) representative colons and group colon lengths, (D) H&E of colonic tissues (10x, 20x, scale 200uM), (E) histological score, intestinal permeability, and (F) colon immune cytokines in control or colitis mice treated with vehicle or TAK-981 at day 7 after 5-day DSS challenge. Mice were treated with TAK-981 (7.5mg/kg) 12 hours before starting DSS challenge and then daily for 4 days. *P<0.05 vs Control, #P<0.05 vs DSS (n=5, One-way ANOVA with Bonferroni’s post-hoc test).